Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.34
HZNP's Cash to Debt is ranked lower than
80% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. HZNP: 0.34 )
Ranked among companies with meaningful Cash to Debt only.
HZNP' s Cash to Debt Range Over the Past 10 Years
Min: 0.07  Med: 0.92 Max: N/A
Current: 0.34
Equity to Asset 0.40
HZNP's Equity to Asset is ranked lower than
80% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. HZNP: 0.40 )
Ranked among companies with meaningful Equity to Asset only.
HZNP' s Equity to Asset Range Over the Past 10 Years
Min: -0.77  Med: 0.45 Max: 0.7
Current: 0.4
-0.77
0.7
Interest Coverage 0.30
HZNP's Interest Coverage is ranked lower than
98% of the 468 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.86 vs. HZNP: 0.30 )
Ranked among companies with meaningful Interest Coverage only.
HZNP' s Interest Coverage Range Over the Past 10 Years
Min: 0.79  Med: 0.79 Max: 0.79
Current: 0.3
F-Score: 5
Z-Score: 0.76
M-Score: -1.37
WACC vs ROIC
9.13%
-5.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 2.76
HZNP's Operating margin (%) is ranked lower than
65% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.72 vs. HZNP: 2.76 )
Ranked among companies with meaningful Operating margin (%) only.
HZNP' s Operating margin (%) Range Over the Past 10 Years
Min: -1841.5  Med: -229.83 Max: 7.31
Current: 2.76
-1841.5
7.31
Net-margin (%) 1.61
HZNP's Net-margin (%) is ranked lower than
68% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.02 vs. HZNP: 1.61 )
Ranked among companies with meaningful Net-margin (%) only.
HZNP' s Net-margin (%) Range Over the Past 10 Years
Min: -1635.12  Med: -324.26 Max: 5.22
Current: 1.61
-1635.12
5.22
ROE (%) 1.18
HZNP's ROE (%) is ranked lower than
67% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.02 vs. HZNP: 1.18 )
Ranked among companies with meaningful ROE (%) only.
HZNP' s ROE (%) Range Over the Past 10 Years
Min: -523.78  Med: -111.48 Max: 4.27
Current: 1.18
-523.78
4.27
ROA (%) 0.50
HZNP's ROA (%) is ranked lower than
65% of the 772 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. HZNP: 0.50 )
Ranked among companies with meaningful ROA (%) only.
HZNP' s ROA (%) Range Over the Past 10 Years
Min: -186.55  Med: -63.12 Max: 1.89
Current: 0.5
-186.55
1.89
ROC (Joel Greenblatt) (%) 88.89
HZNP's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.79 vs. HZNP: 88.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HZNP' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -7948.82  Med: -1996.11 Max: 520.88
Current: 88.89
-7948.82
520.88
Revenue Growth (3Y)(%) 112.60
HZNP's Revenue Growth (3Y)(%) is ranked higher than
98% of the 605 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. HZNP: 112.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HZNP' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -14.50 Max: 112.6
Current: 112.6
0
112.6
» HZNP's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-07)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

HZNP Guru Trades in Q2 2015

RS Investment Management 964,160 sh (New)
Steve Mandel 3,204,972 sh (New)
Jim Simons 1,216,800 sh (+238.54%)
Paul Tudor Jones 137,400 sh (+201.92%)
Steven Cohen 325,000 sh (+38.95%)
» More
Q3 2015

HZNP Guru Trades in Q3 2015

Ron Baron 31,999 sh (New)
Steve Mandel 15,600,988 sh (+386.77%)
RS Investment Management 1,383,550 sh (+43.50%)
Jim Simons 465,912 sh (-61.71%)
Paul Tudor Jones 12,038 sh (-91.24%)
Steven Cohen 900 sh (-99.72%)
» More
Q4 2015

HZNP Guru Trades in Q4 2015

Ken Heebner 205,000 sh (New)
Julian Robertson 823,577 sh (New)
Joel Greenblatt 2,075,017 sh (New)
Paul Tudor Jones 48,570 sh (+303.47%)
RS Investment Management 2,210,448 sh (+59.77%)
Steve Mandel 15,600,988 sh (unchged)
Ron Baron Sold Out
Steven Cohen Sold Out
Jim Simons 302,400 sh (-35.10%)
» More
Q1 2016

HZNP Guru Trades in Q1 2016

Steven Cohen 1,019,400 sh (New)
Ken Heebner 330,000 sh (+60.98%)
Paul Tudor Jones 72,983 sh (+50.26%)
Julian Robertson 868,477 sh (+5.45%)
Jim Simons Sold Out
Steve Mandel 13,997,232 sh (-10.28%)
RS Investment Management 1,453,024 sh (-34.27%)
Joel Greenblatt 1,053,933 sh (-49.21%)
» More
» Details

Insider Trades

Latest Guru Trades with HZNP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:OTCPK:INVVY, NYSE:CTLT, OTCPK:SWPIF, NAS:MDCO, OTCPK:SHPHF, NYSE:DPLO, NAS:IPXL, OTCPK:STDAF, NAS:ENDP, NAS:AKRX, NAS:IRWD, OTCPK:CHSYF, OTCPK:GEDSF, NAS:INNL, NAS:RDUS, NAS:NBIX, NAS:PCRX, NAS:CPXX, NAS:DEPO, OTCPK:GNMLF » details
Traded in other countries:HPR.Germany,
Horizon Pharma PLC is a specialty pharmaceutical company. The Company's product portfolio consists of ACTIMMUNE, DUEXIS, PENNSAID 2% and RAYOS/LODOTRA, which addresses the unmet therapeutic needs in arthritis, pain, inflammatory and/or orphan diseases.

Horizon Pharma PLC was incorporated on March 23, 2010. The Company is a specialty pharmaceutical company commercializing DUEXIS, VIMOVO and RAYOS/LODOTRA, each of which targets unmet therapeutic needs in arthritis, pain and inflammatory diseases. DUEXIS is a proprietary single tablet formulation containing a fixed-dose combination of ibuprofen, one of the widely prescribed NSAIDs, and famotidine, a well-established GI agent used to treat dyspepsia, gastroesophageal reflux disease, or GERD, and active ulcers, in one pill. Ibuprofen has proven anti-inflammatory and analgesic properties and famotidine reduces the stomach acid secretion that can cause upper GI ulcers. VIMOVO is a proprietary fixed-dose multi-layer delayed-release tablet combining an enteric-coated naproxen, an NSAID, core and an immediate-release esomeprazole, a PPI, layer surrounding the core. Naproxen has proven anti-inflammatory and analgesic properties and esomeprazole reduces the stomach acid secretions that can cause upper GI ulcers. RAYOS, known as LODOTRA outside the United States, is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults particularly when accompanied by morning stiffness. DUEXIS and VIMOVO compete with other branded NSAIDs, including Celebrex, marketed by Pfizer Inc. RAYOS/LODOTRA competes in Europe and in the United States with a number of products on the market to treat RA, including corticosteroids, such as prednisone, traditional DMARDs, such as methotrexate and biologic agents, such as HUMIRA and Enbrel.

Top Ranked Articles about Horizon Pharma PLC

Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma
Steven Mandel’s hedge fund, Lone Pine Capital, on July 27 initiated a position in Horizon Pharma Plc (NASDAQ:HZNP), according to GuruFocus Real Time Picks. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 167.33
HZNP's P/E(ttm) is ranked lower than
94% of the 535 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.34 vs. HZNP: 167.33 )
Ranked among companies with meaningful P/E(ttm) only.
HZNP' s P/E(ttm) Range Over the Past 10 Years
Min: 81.83  Med: 159.66 Max: 213.64
Current: 167.33
81.83
213.64
Forward P/E 7.28
HZNP's Forward P/E is ranked higher than
85% of the 65 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.67 vs. HZNP: 7.28 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 167.33
HZNP's PE(NRI) is ranked lower than
94% of the 533 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.24 vs. HZNP: 167.33 )
Ranked among companies with meaningful PE(NRI) only.
HZNP' s PE(NRI) Range Over the Past 10 Years
Min: 81.05  Med: 156.11 Max: 208.89
Current: 167.33
81.05
208.89
Price/Owner Earnings (ttm) 25.18
HZNP's Price/Owner Earnings (ttm) is ranked higher than
61% of the 267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.00 vs. HZNP: 25.18 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
HZNP' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 22.42  Med: 27.41 Max: 31.44
Current: 25.18
22.42
31.44
P/B 1.88
HZNP's P/B is ranked higher than
62% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. HZNP: 1.88 )
Ranked among companies with meaningful P/B only.
HZNP' s P/B Range Over the Past 10 Years
Min: 0.8  Med: 2.30 Max: 14.94
Current: 1.88
0.8
14.94
P/S 2.85
HZNP's P/S is ranked lower than
56% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.59 vs. HZNP: 2.85 )
Ranked among companies with meaningful P/S only.
HZNP' s P/S Range Over the Past 10 Years
Min: 1.34  Med: 4.17 Max: 12.65
Current: 2.85
1.34
12.65
PFCF 7.88
HZNP's PFCF is ranked higher than
87% of the 189 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.95 vs. HZNP: 7.88 )
Ranked among companies with meaningful PFCF only.
HZNP' s PFCF Range Over the Past 10 Years
Min: 7.01  Med: 43.35 Max: 499.62
Current: 7.88
7.01
499.62
POCF 7.55
HZNP's POCF is ranked higher than
82% of the 254 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.49 vs. HZNP: 7.55 )
Ranked among companies with meaningful POCF only.
HZNP' s POCF Range Over the Past 10 Years
Min: 6.73  Med: 37.97 Max: 223.97
Current: 7.55
6.73
223.97
EV-to-EBIT 135.42
HZNP's EV-to-EBIT is ranked lower than
95% of the 526 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.96 vs. HZNP: 135.42 )
Ranked among companies with meaningful EV-to-EBIT only.
HZNP' s EV-to-EBIT Range Over the Past 10 Years
Min: -775.4  Med: -1.65 Max: 219.8
Current: 135.42
-775.4
219.8
EV-to-EBITDA 16.34
HZNP's EV-to-EBITDA is ranked lower than
53% of the 557 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.28 vs. HZNP: 16.34 )
Ranked among companies with meaningful EV-to-EBITDA only.
HZNP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -608  Med: -0.50 Max: 518
Current: 16.34
-608
518
Current Ratio 1.98
HZNP's Current Ratio is ranked lower than
60% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. HZNP: 1.98 )
Ranked among companies with meaningful Current Ratio only.
HZNP' s Current Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.99 Max: 4.39
Current: 1.98
0.16
4.39
Quick Ratio 1.57
HZNP's Quick Ratio is ranked lower than
58% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.78 vs. HZNP: 1.57 )
Ranked among companies with meaningful Quick Ratio only.
HZNP' s Quick Ratio Range Over the Past 10 Years
Min: 0.16  Med: 1.80 Max: 4.27
Current: 1.57
0.16
4.27
Days Inventory 69.20
HZNP's Days Inventory is ranked higher than
75% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.06 vs. HZNP: 69.20 )
Ranked among companies with meaningful Days Inventory only.
HZNP' s Days Inventory Range Over the Past 10 Years
Min: 13.1  Med: 48.48 Max: 184.95
Current: 69.2
13.1
184.95
Days Sales Outstanding 124.86
HZNP's Days Sales Outstanding is ranked lower than
80% of the 625 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.75 vs. HZNP: 124.86 )
Ranked among companies with meaningful Days Sales Outstanding only.
HZNP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 64.38  Med: 89.59 Max: 124.99
Current: 124.86
64.38
124.99
Days Payable 94.93
HZNP's Days Payable is ranked higher than
66% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.79 vs. HZNP: 94.93 )
Ranked among companies with meaningful Days Payable only.
HZNP' s Days Payable Range Over the Past 10 Years
Min: 27.59  Med: 193.90 Max: 410.36
Current: 94.93
27.59
410.36

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.26
HZNP's Price/Projected FCF is ranked higher than
53% of the 303 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.34 vs. HZNP: 2.26 )
Ranked among companies with meaningful Price/Projected FCF only.
HZNP' s Price/Projected FCF Range Over the Past 10 Years
Min: 2.3  Med: 8.73 Max: 29.51
Current: 2.26
2.3
29.51
Price/Median PS Value 0.74
HZNP's Price/Median PS Value is ranked higher than
81% of the 662 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.09 vs. HZNP: 0.74 )
Ranked among companies with meaningful Price/Median PS Value only.
HZNP' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.38  Med: 1.04 Max: 2.7
Current: 0.74
0.38
2.7
Earnings Yield (Greenblatt) (%) 0.74
HZNP's Earnings Yield (Greenblatt) (%) is ranked lower than
67% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. HZNP: 0.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HZNP' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.5  Med: 0.70 Max: 1.9
Current: 0.74
0.5
1.9

More Statistics

Revenue (TTM) (Mil) $848.6
EPS (TTM) $ 0.09
Beta1.45
Short Percentage of Float11.71%
52-Week Range $12.86 - 39.49
Shares Outstanding (Mil)160.36

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 1,006 1,167 1,307
EPS ($) 2.23 3.64 3.25
EPS w/o NRI ($) 2.23 3.64 3.25
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for HZNP

Headlines

Articles On GuruFocus.com
Julian Robertson Buys 8 New Stakes in 4th Quarter Mar 09 2016 
Sheets Smith Wealth Management Buys Companies With no Debts Sep 01 2015 
Horizon Pharma Leads Stock Returns in Health Care Industry Aug 24 2015 
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
M&A’s Driving The Stock Indexes Ahead Apr 06 2015 
Biotech Effectiveness: Horizon Pharma, Zafgen, XOMA Corp Mar 09 2015 

More From Other Websites
Tweets on the Street: Pimco's Eurozone Concerns, Shkreli on Horizon Pharma Jun 10 2016
Nuvo Pharmaceuticals™ Announces Director Election Results of its Annual General Meeting Jun 07 2016
Jazz Pharma Started At Buy; Visa And Wal-Mart Upgraded Jun 06 2016
Specialty Pharma: After the M&A Fueled Super Cycle Jun 06 2016
Coverage initiated on Horizon Pharma by Goldman Jun 06 2016
Sell Alert: These 5 Stocks Look Toxic Right Now Jun 03 2016
Horizon Pharma plc to Participate in Jefferies 2016 Healthcare Conference Jun 02 2016
Horizon Pharma plc to Participate in Jefferies 2016 Healthcare Conference Jun 02 2016
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice... Jun 01 2016
Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice... Jun 01 2016
Horizon Pharma Plc breached its 50 day moving average in a Bullish Manner : HZNP-US : May 26, 2016 May 26 2016
Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well May 25 2016
Loving 'unloved' stocks: Pro May 23 2016
Horizon (HZNP) to Buy Global Rights to Actimmune, Stock Down May 20 2016
Horizon Pharma plc to Acquire Worldwide Rights to Interferon Gamma-1b From Boehringer Ingelheim... May 19 2016
HORIZON PHARMA PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 19 2016
Horizon Pharma plc to Acquire Worldwide Rights to Interferon Gamma-1b From Boehringer Ingelheim... May 19 2016
Horizon Pharma plc to Participate in UBS Global Healthcare Conference May 18 2016
Horizon Pharma plc to Participate in UBS Global Healthcare Conference May 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)